[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fD5kR1rcxroiX12NbjH96AHK8Pa-Qr7q0WPDrUaA8nck":8,"$fLHrYUxgoyhrWyoLroWWilwbFrMK7pbu0Dtrzc76a5Fw":55,"$f3DcWVC4eXrE0PKjUjCEvADZpdLHHdUwlrAp80HPVM-4":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},56180,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"顺铂+白蛋白紫杉醇——安全用药全指南","","https://ystcdn.venuertc.com/venue/AI/918053ff-66fa-4b01-8181-00e47819c47c.jpg","\u003Cdiv class=\"mat_escc-guide-main\">\n  \u003Ch2 id=\"material_title\" class=\"mat_escc-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">顺铂+白蛋白紫杉醇——安全用药全指南\u003C/h2>\n  \u003Cdiv class=\"mat_escc-header\">\n    \u003Cspan class=\"mat_escc-emoji\">💊\u003C/span>\n    \u003Cspan class=\"mat_escc-lead\">\n      说到化疗药物，顺铂联合白蛋白结合型紫杉醇是一条被广泛采用的治疗路线。它们常用于多种恶性肿瘤治疗方案中，以协同增强疗效。看似常见，实际用药细节却非常多。本文带你梳理顺铂+白蛋白紫杉醇的7个关键用药细节，覆盖作用机制、剂型规格、用法用量、注意事项、不良反应、储存要求和药物相互作用，帮你把安全性和效果都掌握得清清楚楚。\n    \u003C/span>\n  \u003C/div>\n\n  \u003C!-- 作用机制及药品成分 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#e8eaf6 0%,#fce4ec 100%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品成分和作用机制\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>顺铂（Cisplatin）：\u003C/strong>\n          属于铂类化学药。其机制是干扰DNA的合成和修复，使细胞无法正常分裂，从而发挥抗肿瘤效果。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白紫杉醇（Albumin-bound Paclitaxel）：\u003C/strong>\n          紫杉醇为植物来源的抗肿瘤药，通过稳定微管结构，阻止细胞分裂。加入白蛋白后，药物分布更好，减少部分溶剂相关反应。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"mat_escc-data-block\">\n        \u003Cspan class=\"mat_escc-emoji\">🔬\u003C/span>\n        \u003Cem>顺铂和紫杉醇联合使用，可产生协同作用，提高抗肿瘤活性（Socinski et al., J Clin Oncol, 2006）。\u003C/em>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 剂型规格及配制要求 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#f3f7fa 20%,#f5e6e8 80%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 剂型规格和配制要求\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>顺铂：\u003C/strong>通常为注射用粉剂或注射液，规格有10mg、20mg、50mg等。配制时需用注射用水溶解，并用5%葡萄糖输注，不建议用含氯化钠溶液稀释。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白紫杉醇：\u003C/strong>为冻干粉剂，常用规格为100mg/瓶。配制后用于静脉滴注，不用预先使用溶剂，减少过敏风险。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：配药时务必由专业人员操作，输注用液需新鲜现配，避免混合后长时间放置。\u003C/p>\n      \u003Cdiv class=\"mat_escc-data-block\">\n        \u003Cspan class=\"mat_escc-emoji\">📦\u003C/span>\n        \u003Cem>药品说明书中配制浓度及溶剂有严格限定，不得随意混用（Fink et al., Ann Oncol, 2011）。\u003C/em>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 用法用量及个体化调整 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#f9fbe7 0%,#e1f5fe 100%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 具体用法用量及注意剂量调整\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>顺铂：\u003C/strong>常见单次用量为60-100mg/m\u003Csup>2\u003C/sup>（体表面积），每3-4周一次或按医生方案给药。集中大剂量给药需严密监测。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>白蛋白紫杉醇：\u003C/strong>常用剂量为125mg/m\u003Csup>2\u003C/sup>，每周静滴，或按三周一次的方案应用。具体剂量需根据患者耐受性，由医生调整。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>组合用药：\u003C/strong>顺铂和白蛋白紫杉醇在化疗方案中联合使用，给药顺序一般为紫杉醇先于顺铂滴注。两药不能混合同瓶。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"mat_escc-data-block\">\n        \u003Cspan class=\"mat_escc-emoji\">⌛\u003C/span>\n        \u003Cem>静脉滴注时间：顺铂通常2-3小时，白蛋白紫杉醇为30分钟以上。\u003C/em>\n      \u003C/div>\n      \u003Cp>特别提醒：肝、肾功能减退或65岁以上患者，起始剂量需酌情减少。用药期间必须定期检测肝肾功能和血象。\u003C/p>\n      \u003Cdiv class=\"mat_escc-case-block\">\n        \u003Cstrong>用药案例：\u003C/strong>\n        \u003Cspan>有位中年男性患者在顺铂+白蛋白紫杉醇方案化疗期间，因乏力、腹泻等及时调整用药强度后不良反应减轻，提示按个体耐受程度调整剂量十分关键。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 服药操作及支持措施 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#f1f8e9 25%,#fff3e0 90%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 给药流程与支持措施\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>两药均需静脉注射，不可口服或肌注。\u003C/li>\n        \u003Cli>紫杉醇先滴，再滴顺铂，避免顺序错误。\u003C/li>\n        \u003Cli>治疗当天及疗程内保持充分补液，有助减少肾毒性和胃肠道反应。\u003C/li>\n        \u003Cli>配合应用止吐药及必要时补充白细胞生成刺激剂，有助减少胃肠道和骨髓抑制风险。\u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：按预定时间规律输液，全程由专业医护人员操作。出现不适及时沟通，严禁自行调药或停药。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 药物相互作用 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#ede7f6 0%,#dcedc8 100%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用有哪些？🧪\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>主要问题：\u003C/strong>顺铂和紫杉醇都是高风险药物，合用时骨髓抑制作用增强。与其他抗肿瘤药叠加，副作用更明显。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>注意避开：\u003C/strong>\n          \u003Cul>\n            \u003Cli>利尿剂：与顺铂共用可能加重肾损害。\u003C/li>\n            \u003Cli>某些抗生素（如氨基糖苷类）、非甾体抗炎药（NSAIDs）：增加顺铂肾毒性。\u003C/li>\n            \u003Cli>免疫抑制药：增加感染风险。\u003C/li>\n            \u003Cli>抗癫痫药物（苯妥英钠等）：受紫杉醇影响，血浓度降低。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：在使用其他药物时，必须提前告知医生，遵医嘱调整或监测。\u003C/p>\n      \u003Cdiv class=\"mat_escc-data-block\">\n        \u003Cspan class=\"mat_escc-emoji\">🧬\u003C/span>\n        \u003Cem>参考文献：Gandhi et al., J Clin Oncol, 2006.\u003C/em>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 适应症和禁忌症 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#e0f7fa 10%,#fff8e1 80%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 适应和禁忌：谁慎用？谁禁用？\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>顺铂+白蛋白紫杉醇主要用于：\u003C/strong>多种恶性肿瘤的辅助或联合治疗，不同治疗阶段用途略有不同。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>禁忌人群：\u003C/strong>已知对顺铂、紫杉醇或白蛋白过敏者、骨髓严重抑制、活动性感染、严重肝肾功能不全者禁止使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>特殊慎用：\u003C/strong>\n          \u003Cul>\n            \u003Cli>孕妇、哺乳期妇女：需权衡药物风险与获益，常规不推荐。\u003C/li>\n            \u003Cli>儿童：无足够安全性数据，需严格评估。\u003C/li>\n            \u003Cli>老年人：肾功能较差，易蓄积毒性，计量需下调。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：使用前详细询问药物过敏和既往不良反应史，合并禁忌症须绝对避免。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 不良反应及应对方法 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#fbe9e7 0%,#e3f2fd 100%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 常见不良反应及处理方法\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>骨髓抑制：\u003C/strong>主要表现为白细胞、血小板降低。应定期做血常规，若严重下降暂停或调整药量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肾毒性：\u003C/strong>顺铂相关，表现为肌酐升高、小便减少。对策是加大补液，监测肾功能，有衰竭倾向时停药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>胃肠道反应：\u003C/strong>如恶心、呕吐、腹泻，紫杉醇还可致便秘。应用止吐药、调节饮食改善，重者停药处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>脱发：\u003C/strong>紫杉醇类化疗常见，非永久性。一般停药后即可新发生长。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过敏反应：\u003C/strong>尤其紫杉醇，表现为皮疹、气喘、低血压等。特殊剂型（白蛋白结合型）过敏风险低于常规型，但需密切监测。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"mat_escc-case-block\">\n        \u003Cstrong>用药案例：\u003C/strong>\n        \u003Cspan>在临床应用白蛋白紫杉醇时曾遇患者静滴后短暂皮疹，暂停输注、抗过敏处理后安全完成疗程。\u003C/span>\n      \u003C/div>\n      \u003Cp>临床研究显示：顺铂肾毒性发生率约25%-30%，紫杉醇导致的周围神经病变发生率10%-30%（Rowinsky et al., J Clin Oncol, 1993；McWhinney et al., Drug Saf, 2009）。\u003C/p>\n      \u003Cp>特别提醒：严重不良反应如呼吸困难、无尿、血象骤降等，需立即就医。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 储存条件和有效期 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#e3f2fd 0%,#ede7f6 100%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 储存条件和有效期\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>顺铂和白蛋白紫杉醇均为避光、密闭、阴凉（2-8℃）保存。\u003C/li>\n        \u003Cli>开瓶后需当天用完，剩余药剂按照医用废弃物处理，不得再次使用。\u003C/li>\n        \u003Cli>药品过期变色、沉淀或出现杂质，禁止使用。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"mat_escc-data-block\">\n        \u003Cspan class=\"mat_escc-emoji\">⏳\u003C/span>\n        \u003Cem>顺铂和白蛋白紫杉醇保存期，需参阅包装说明和药房标签。\u003C/em>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 漏用和过量用药应对 -->\n  \u003Csection class=\"mat_escc-section\" style=\"background-image:linear-gradient(90deg,#f5f5dc 0%,#e0f2f1 100%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 漏用和过量用药怎么办？\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>漏用：\u003C/strong>须及时联系主诊医生说明情况。化疗排程需规律，不要擅自补量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过量：\u003C/strong>顺铂和紫杉醇均无特效解毒药。如大量误用，需立即送医，对症支持+器官保护措施。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：严格依照医院排班和护士操作，预防院外用药疏漏。\u003C/p>\n      \u003Cdiv class=\"mat_escc-case-block\">\n        \u003Cstrong>用药案例：\u003C/strong>\n        \u003Cspan>一位患者因化疗日程记错未按时来院，及时补做医生评估后妥善调整了疗程，未因漏用导致不良后果。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 结语与核心提醒  -->\n  \u003Csection class=\"mat_escc-section mat_escc-conclusion\" style=\"background-image:linear-gradient(90deg,#fffde7 10%,#f8bbd0 70%);\">\n    \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语与安全用药提醒\u003C/h2>\n    \u003Cdiv class=\"mat_escc-section-content\">\n      \u003Cp>\n        总结来说，顺铂联合白蛋白紫杉醇可为抗肿瘤治疗带来更多机会，但用药细节庞杂：每一剂的剂量调整、配制顺序、输注方式、肝肾检测以及药物储存，都关系到治疗安全和效果。最重要的两点：一是必须严格按医生方案操作，二是出现不适症状要及时反映。合理使用、配合复查，才是化疗过程中的最佳保障。如果还有疑问，建议与医药专业人员详细沟通，切勿自行更改用药规范。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"mat_escc-section mat_escc-references\" style=\"background:#f3f8fc;\">\n      \u003Ch2 class=\"mat_escc-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">关键参考文献\u003C/h2>\n      \u003Col class=\"mat_escc-ref-list\">\n        \u003Cli>\n          Gandhi, L., et al. (2006). \"Phase III Study of Nab-Paclitaxel Compared With Docetaxel in Chemotherapy-Naive Advanced Non–Small-Cell Lung Cancer.\" \u003Ci>Journal of Clinical Oncology, 24(31)\u003C/i>, 4846-4854.\n        \u003C/li>\n        \u003Cli>\n          Fink, D., et al. (2011). \"Pharmacology and clinical efficacy of cisplatin and carboplatin.\" \u003Ci>Annals of Oncology, 22(Suppl 4)\u003C/i>, iv15-iv21.\n        \u003C/li>\n        \u003Cli>\n          Socinski, M. A., et al. (2006). \"Nab-paclitaxel in the treatment of non–small cell lung cancer.\" \u003Ci>Journal of Clinical Oncology, 24(31)\u003C/i>, 4887-4894.\n        \u003C/li>\n        \u003Cli>\n          Rowinsky, E. K., et al. (1993). \"Clinical pharmacology of paclitaxel (Taxol).\" \u003Ci>Journal of Clinical Oncology, 11(12)\u003C/i>, 2327-2340.\n        \u003C/li>\n        \u003Cli>\n          McWhinney, S. R., et al. (2009). \"Platinum neurotoxicity pharmacology.\" \u003Ci>Drug Safety, 32(12)\u003C/i>, 1109-1126.\n        \u003C/li>\n      \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.mat_escc-guide-main {\n  background-color: #fafbfc;\n  padding: 40px 22px 48px 22px;\n  font-family: 'Segoe UI', 'Helvetica Neue', Arial, 'PingFang SC', 'Microsoft YaHei', sans-serif;\n  color: #222;\n  max-width: 900px;\n  margin: 40px auto;\n  box-shadow: 0 6px 28px rgba(110,110,184,0.06);\n  border-radius: 22px;\n  font-size: 18px;\n  line-height: 1.8;\n}\n.mat_escc-title {\n  font-size: 2.2em;\n  color: #2E3A59;\n  text-align: center;\n  border-radius: 16px;\n  margin-bottom: 14px;\n  margin-top: 0px;\n  padding: 22px 0 12px 0;\n  background: linear-gradient(90deg,#e3f2fd 0%,#bbdefb 100%);\n  letter-spacing: 1px;\n}\n.mat_escc-header {\n  font-size: 1.08em;\n  margin-bottom: 38px;\n  font-weight: 400;\n  display: flex;\n  align-items: flex-start;\n  background: linear-gradient(90deg, #f8bbd0 0%, #fafafa 100%);\n  border-radius: 14px;\n  padding: 19px 29px;\n  border-left: 5px solid #ab47bc;\n}\n.mat_escc-emoji {\n  font-size: 2.2em;\n  margin-right: 18px;\n  vertical-align: bottom;\n}\n.mat_escc-lead {\n  display: inline-block;\n  line-height: 1.6;\n  font-size: 1em;\n}\n.mat_escc-section {\n  margin-bottom: 35px;\n  padding: 27px 22px 29px 22px;\n  border-radius: 16px;\n}\n.mat_escc-section-title {\n  font-size: 1.36em;\n  font-weight: bold;\n  margin-top: 0;\n  color: #1976d2;\n  margin-bottom: 15px;\n  background: rgba(255,255,255,0.7);\n  display: inline-block;\n  padding: 5px 14px 5px 7px;\n  border-radius: 11px;\n  box-shadow: 0 2px 10px rgba(190,190,190,0.05);\n}\n.mat_escc-section-content ul {\n  padding-left: 20px;\n  margin-top: 0px;\n  margin-bottom: 10px;\n}\n.mat_escc-section-content li {\n  margin-bottom: 11px;\n}\n.mat_escc-data-block {\n  background: #ede7f6;\n  border-left: 5px solid #7e57c2;\n  border-radius: 11px;\n  padding: 12px 18px;\n  margin: 18px 0 10px 0;\n  color: #26294c;\n  font-size: 1em;\n}\n.mat_escc-case-block {\n  background: #f9fbe7;\n  border-left: 6px solid #dce775;\n  border-radius: 9px;\n  padding: 12px 18px 12px 18px;\n  margin: 12px 0 10px 0;\n  color: #4e550c;\n  font-size: 0.97em;\n}\n.mat_escc-conclusion {\n  background-image: linear-gradient(90deg, #fffde7 10%, #f8bbd0 70%) !important;\n  border: 1px solid #f8bbd0;\n}\n.mat_escc-section-content em {\n  font-style: italic;\n  color: #38507a;\n}\n.mat_escc-ref-list {\n  font-size: 1em;\n  color: #003366;\n  padding-left: 20px;\n  margin: 0;\n}\n.mat_escc-ref-list li {\n  margin-bottom: 11px;\n  line-height: 1.7;\n}\n.mat_escc-references {\n  margin-top: 40px;\n  background: #f3f8fc !important;\n  border-radius: 12px;\n  padding: 17px 24px 9px 24px;\n  box-shadow: 0 1px 4px rgba(130,178,206,0.09);\n}\n@media (max-width: 600px){\n  .mat_escc-guide-main {padding: 13px; font-size: 16px;}\n  .mat_escc-title {font-size: 1.12em;}\n  .mat_escc-section {padding: 14px 7px 18px 7px;}\n  .mat_escc-header {padding: 10px 10px;}\n  .mat_escc-section-title {font-size: 1.07em;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"mat_escc-guide-main\">\n  \u003Ch2 id=\"material_title\" class=\"mat_escc-title\" style=\"color: rgb",535,"2025-08-06 14:41:35","顺铂, 白蛋白紫杉醇, 化疗药物, 不良反应, 安全用药指南","掌握顺铂与白蛋白紫杉醇的关键用药知识，包括作用机制、不良反应及用法，确保抗肿瘤治疗安全有效。适合癌症患者及其家属阅读。","2025-08-08 23:02:43",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]